Medindia

X

New Solution for Malnourished Dialysis Patients

Tuesday, September 2, 2008 General News J E 4
Advertisement
BOOTHWYN, Pa., Sept. 2 The number of Chronic KidneyDisease (CKD) patients requiring hemodialysis, considered Stage 5 CKD, isgrowing every year in spite of medical advances. This growth is fueled by theaging baby boomer population and the diabetes epidemic in the United States.There were nearly 100,000 new cases of Stage 5 CKD in 2005 alone, according tothe United States Renal Data System, and approximately 600,000 in total today.That number is expected to climb 76% by 2020 and cost Medicare nearly$54 billion. (1, 2)

It is estimated that up to 70% of dialysis patients suffer from varyingdegrees of malnutrition that can result in unwanted weight loss and low bloodprotein levels, specifically, albumin.(3) Low body mass index coupled with lowserum albumin have been strongly linked to mortality and close to 60% of newdialysis patients begin therapy with albumin levels below the lower limit ofnormal.(4, 5, 6) For dialysis patients who do not respond adequately to astandard approach, like liberalized diet and oral supplements, proteinmalnutrition and/or calorie malnutrition remain significant problems.

To address the specific nutritional needs of this patient group, PentecHealth developed a new line of patent-pending Intradialytic ParenteralNutrition (IDPN) solutions called PROPLETE(TM). IDPN is a type of IV nutritionadministered through the dialysis machine directly into the bloodstream whilepatients receive dialysis. PROPLETE(TM) is formulated to address the proteinmalnourished dialysis population and has specific advantages for diabetespatients, as well as those with fluid management challenges.

Eileen Moore, CNSD, R.D, L.D., a nationally recognized expert on IDPN,believes the new formulation may be of additional benefit to malnourishedhemodialysis patients with diabetes. "Traditional formulations for IDPN havebeen particularly troublesome for malnourished patients with diabetes. Theyoften require close supervision of blood glucose and may require insulinadministration. The unique formulation of PROPLETE(TM) provides an option forthese patients and may make managing their glucose and fluids easier."

"The introduction of PROPLETE(TM) reaffirms our commitment to patients,innovation and the renal nutrition market. Pentec Health has a 25 year historyof offering traditional IDPN therapy and the introduction of PROPLETE(TM)allows us to extend the benefits to a broader range of patients," said JoeCosgrove, President and CEO of Pentec Health. "Given the current magnitude ofdiabetes, we are confident that PROPLETE(TM) will play a significant role inaddressing unmet renal nutritional needs."

PROPLETE(TM) is available exclusively from Pentec Health and can beordered immediately to begin addressing the malnutrition needs of thehemodialysis population.

About Pentec Health, Inc.

For 25 years, Pentec Health has been an industry leader in providingSpecialty Infusion Services nationwide to patients who require access tocomplex pharmaceutical products and services outside of the hospital setting.

Pentec Health provides Intraperitoneal Parenteral Nutrition (IPN) andIntradialytic Parenteral Nutrition (IDPN) products and services to dialysiscenters for their malnourished dialysis patients; and, as a JCAHO accreditedhome care provider, offers specialty in-home infusion services for highlycomplex conditions that are underserved by traditional home care providers.Pentec Health offers preparation and clinical management of drug therapies,skilled nursing support, reimbursement services and unparalleled carecoordination to patients with acute and chronic conditions.

For more information about Pentec Health, Inc. visit,http://www.pentechealth.com.

Joe Cosgrove, President and CEO, Pentec Health, Inc., +1-610-494-8700,jcosgrove@pentechealth.com or contact Michael Abens+1-610-494-8700, mabens@pentechealth.com


Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Debiopharm and EPFL Sign Research Project Agreemen...
S
Survey Highlights How Family Support and Finding a...